Data (Use and Access) Bill [HL]

Debate between Viscount Camrose and Lord Bethell

Committee stage
Wednesday 18th December 2024 Grand Committee

[Lord Bethell (Con)]

My Lords, I rise to make a brief but emphatic comment from the health constituency. We in the NHS have been victims of appalling cyber- hacking. The pathology labs in south London were hacked and that cost many lives. It is an example of where the world is going in the future unless we act promptly. The emphatic call for quick action so that government keeps up with world changes is really well made. I ask the Minister to reflect on that.

[Viscount Camrose (Con)]

My Lords, I, too, shall speak very briefly, which will save valuable minutes in which I can order my CyberUp Christmas mug.

Amendments 156A and 156B add to the definition of unauthorised access, so that it includes instances where a person who accesses data in the reasonable knowledge that the controller would not consent if they knew about the access or the reason for the access, and this person is not empowered to access by an enactment. Amendment 156B introduces defences to this new charge. Given the amount of valuable personal data held by controllers, as our lives have moved increasingly online—as many speakers in this debate have vividly brought out—there is absolutely clear merit not just in this idea but in the pace implied, which many noble Lords have called for. There is a need for real urgency here, and I look forward to hearing more detail from the Minister.

--- Later in debate ---

[Viscount Camrose (Con)]

My Lords, the UK is a world leader in genomics research. This research will no doubt result in many benefits, particularly in the healthcare space. However, genomics data can be, and increasingly is, exploited for deeply concerning purposes, including geostrategic ones.

Western intelligence agencies are reportedly becoming increasingly concerned about China using genomic data and biotechnology for military purposes. The Chinese Government have made it clear that genomics plays a key part in the civilian-military doctrine. The 13th five-year plan for military-civil fusion calls for the cross-pollination of military and civilian technology such as biotechnology. This statement, taken in conjunction with reports that the Beijing Genomics Institute—the BGI—in collaboration with the People’s Liberation Army, is looking to make ethnically Han Chinese soldiers less susceptible to altitude sickness, makes for worrying reading. Genetically engineered soldiers appear to be moving out of fiction and towards reality.

The global genomics industry has grown substantially as a result of the Covid-19 pandemic and gene giant BGI Group and its affiliated MGI Tech have acquired large databases of DNA. Further, I note that BGI has widespread links to the Chinese state. It operates the Government’s key laboratories and national gene bank, itself a vast repository of DNA data drawn from all over the world. A Reuters investigation found that a prenatal test, NIFTY, sold by BGI to expectant mothers, gathered millions of women’s DNA data. This prenatal test was developed in collaboration with the Chinese military.

For these reasons, I think we must become far more protective of genomic data gathered from our population. While many researchers use genomic data to find cures for terrible diseases, many others, I am afraid, would use it to do us harm. To this end, I have tabled Amendment 199 to require the Secretary of State and the Information Commissioner to conduct frequent risk assessments on data privacy associated with genomics and DNA companies headquartered in countries that are systemic competitors or hostile actors. I believe this will go some way to preventing genomic data transfer out of the UK and to countries such as China that may use it for military purposes. I beg to move.

[Lord Bethell (Con)]

My Lords, I strongly support this amendment. As a former Minister, I was at the front line of genomic data and know how powerful it currently is and can be in the future. Having discussed this with the UK Biobank, I know that the issue of who stores and processes genomic data in the UK is a subject of huge and grave concern. I emphasise that the American Government have moved on this issue already and emphatically. There is the possibility that we will be left behind in global standards and will one day be an outlier if we do not close this important and strategically delicate loophole. For that reason, I strongly support this amendment.